Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa open-label extension in IL-18 driven monogenic autoinflammatory conditions
2018-003199-10Phase 3Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tadekinig alfa in NLRC4-associated autoinflammatory disease (NLRC4-AID) and X-linked lymphoproliferative disease type 2 (XLP2), sponsored by AB2 Bio Ltd. Primary endpoint: Reports of adverse events. Started Oct 2018; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
NLRC4-associated autoinflammatory disease (NLRC4-AID)X-linked lymphoproliferative disease type 2 (XLP2)
Beyond the preview
Go deeper on 2018-003199-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003199-10.